Peripartum cardiomyopathy: postpartum decompensation and use of non-invasive cardiac output monitoring

Int J Obstet Anesth. 2014 Feb;23(1):66-70. doi: 10.1016/j.ijoa.2013.10.008. Epub 2013 Nov 1.

Abstract

The utility of a non-invasive cardiac output monitor (NICOM™) in guiding the peripartum management and identification of postpartum complications in a patient with severe peripartum cardiomyopathy is reported. A 31-year-old nulliparous woman at 35 weeks of gestation presented with a three-week history of worsening dyspnea and progressive functional deterioration. A transthoracic echocardiogram showed severe left ventricular systolic dysfunction with an ejection fraction <20%. Cardiac status was monitored using NICOM™ during labor and delivery. The baseline values were: cardiac output 5.3 L/min, total peripheral resistance 1549 dynes.sec/cm(5), stroke volume 42.1 mL and stroke volume variation 18%. She received early epidural analgesia during labor, titrated slowly with a loading dose of 0.0625% bupivacaine 10 mL and fentanyl 25 μg, followed by patient-controlled epidural analgesia (0.0625% bupivacaine with fentanyl 2 μg/mL, infusion at 10 mL/h, bolus dose 5 mL and lockout interval 10 min). After epidural drug administration, total peripheral resistance decreased, cardiac output increased, and satisfactory analgesia was obtained. She had an uneventful vaginal delivery with a forceps-assisted second stage after prophylactic administration of furosemide 20 mg. NICOM™ was discontinued after delivery. Fifteen hours post-delivery, the patient developed cardiogenic shock, which resolved after aggressive therapy with inotropes and furosemide. NICOM™ can be used to guide treatment during labor and delivery in patients with critical peripartum cardiomyopathy. We suggest that use of NICOM™ be extended into the postpartum period to detect signs of cardiac decompensation in such patients.

Keywords: Cardiogenic shock; NICOM™; Peripartum cardiomyopathy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cardiac Output*
  • Cardiomyopathy, Dilated / complications
  • Cardiomyopathy, Dilated / diagnosis*
  • Cardiomyopathy, Dilated / drug therapy
  • Cardiotonic Agents / therapeutic use
  • Delivery, Obstetric
  • Diuretics / therapeutic use
  • Female
  • Furosemide / therapeutic use
  • Humans
  • Monitoring, Physiologic / methods*
  • Peripartum Period*
  • Postpartum Period*
  • Pregnancy
  • Shock, Cardiogenic / complications
  • Shock, Cardiogenic / diagnosis*
  • Shock, Cardiogenic / drug therapy

Substances

  • Cardiotonic Agents
  • Diuretics
  • Furosemide